Two of Clinigen Group PLC’s (LON:CLIN) jetlag treatments have been granted marketing authorisations by the UK’s medicines regulator.
As the Medicines and Healthcare products Regulatory Agency has now licensed them, the Melatonin drops and tablets can now be prescribed right away. They can also be sold directly to wholesalers.
Previously, the treatments could only be prescribed when doctors had exhausted all other avenues.
Given the likely sales boost from being licensed, Clinigen expects the treatments will be a “modest contributor of growth” within the commercial medicines business this year, offsetting a forecast decline in the unlicensed medicines division.
“This approval will ensure healthcare professionals can manage adult patients experiencing jet-lag with a licensed product, where before there was none,” said chief executive Shaun Chilton.
“Identifying and developing products to offer licensed options to prescribers and patients is an important part of our strategy in Commercial Medicines. We are continuing to explore and invest to further strengthen and diversify the portfolio.”
Havnig opened lower, Clinigen shares were up 1.2% to 1,021p on Wednesday afternoon, valuing the company at £1.3bn.
--Adds share price--